echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: HSV-1G207 oncolytic virus therapy for high-grade glioma in children

    NEJM: HSV-1G207 oncolytic virus therapy for high-grade glioma in children

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    High-grade gliomas account for 8%-10% of children's brain tumors.


    Childhood Immunization

    Recently, researchers conducted a phase I clinical study to evaluate the efficacy and safety of G207 oncolytic virus therapy.


    Recently, researchers conducted a phase I clinical study to evaluate the efficacy and safety of G207 oncolytic virus therapy.


    The study adopted a 3+3 design, and biopsy confirmed the participation of children with recurrent or progressive supratentorial brain tumors.


    Twelve patients with high-grade glioma received G207 treatment, ranging in age from 7 to 18 years old.


    11 patients had imaging, neuropathology or clinical remission, and the average overall survival time of the patients was 12.


    Studies have found that intratumoral injection of G207 or combined radiotherapy can significantly alleviate the condition of relapsed or progressive high-grade gliomas in children, and it is well tolerated .


    Intratumoral injection of G207 or combined radiotherapy can significantly alleviate the condition of patients with recurrent or progressive high-grade glioma in children, and is well tolerated.


    Original source:

    Gregory K.


    Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.